CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
The FDA has approved GlaxoSmithKline’s Tafinlar (dabrafenib) and Mekinist (trametinib) oral oncology treatments. Tafinlar is indicated as a single-agent oral treatment for unresectable melanoma or metastatic melanoma in adult patients with BRAF V600E mutation.
Read More »